First step toward a treatment for rare lung and liver disease
Knowledge-focused
Completed
This early-stage study tested a new drug called WVE-006 in 47 healthy volunteers to see if it is safe and how the body processes it. The goal is to find the right dose for future studies in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs …
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Knowledge-focused
Last updated May 05, 2026 11:54 UTC